Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck releases contraceptive Nexplanon in US
The contraceptive has received FDA approval for the prevention of pregnancy in women for up to three years. Nexplanon should be removed by the end of the third
The contraceptive has received FDA approval for the prevention of pregnancy in women for up to three years. Nexplanon should be removed by the end of the third
The agreement signed in December 2009 for a period of two years, has been extended by Bristol-Myers Squibb for an additional six months term to June 2012. As
As per the agreement, both the companies will develop multi-specific products with extended half-lives, by exploiting the features of Nanobody. Ablynx will receive an upfront payment of EUR20m
The ChartAccess comprehensive EHR solution is believed to help health care centers overcome the cost, speed of implementation, and usability obstacles. Consistent, quality patient care will be enabled
Kyorin Pharmaceutical has discovered and developed Imidafenacin. Kyorin Pharmaceutical grants Daiichi Sankyo rights to activities related to the development and marketing of Imidafenacin in Brazil, as per the
A series of data points including intermediates contents, purity, quality, stability and stereochemistry were collected and compared it with the national standard of Azithromycin API that were issued
Epratuzumab is a humanised monoclonal antibody targeting CD22 and modulating B-cell activity. The data supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of
Cimzia is a PEGylated anti-TNF (Tumor Necrosis Factor), which has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Cimzia showed rapid and sustained
The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] was a five-arm, global phase 2b randomized, double-blind, placebo controlled
Vismodegib is an investigational, oral, targeted medicine which selectively inhibits signaling in the Hedgehog pathway and treats adults with advanced basal cell carcinoma (BCC). The vismodegib application includes